IL-15, a pleiotropic cytokine, stimulates generation of NK, NK-T, γδ, ILC1, and memory CD8
T cells. IL-15 disorders play pathogenetic roles in organ-specific autoimmune diseases …

Epigenomes enable the rectification of disordered cancer gene expression, thereby
providing new targets for pharmacological interventions. The clinical utility of targeting …

Valemetostat tosilate (valemetostat; EZHARMIA®), a selective dual inhibitor of histone-lysine
N-methyltransferases enhancer of zeste homolog 1 and 2 (EZH1/2), is being developed by …

Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor
prognosis and few treatment options for patients with relapsed, recurrent, or refractory …

The number of patients with primary cutaneous lymphoma (PCL) relative to other non-
Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical …

Adult T-cell leukemia/lymphoma (ATL) is an aggressive neoplasm immunophenotypically
resembling regulatory T cells, associated with human T-cell leukemia virus type-1. Here, we …

Immune checkpoint inhibitors are a powerful new tool in the treatment of cancer, with
prolonged responses in multiple diseases, including hematologic malignancies, such as …

Abstract Phosphoinositide-specific phospholipase Cs (PLCs) are expressed in all
mammalian cells and play critical roles in signal transduction. To obtain a comprehensive …

Mogamulizumab is a first‐in‐class IgG1k monoclonal antibody that selectively targets the
chemokine receptor type 4. The drug has received Food and Drug administration …

Adult T‐cell leukemia/lymphoma (ATL) is a mature T‐cell neoplasm and is classified into
four subtypes (acute, lymphoma, chronic, and smoldering) according to the Shimoyama …